Tumors that display high levels of genetic diversity are often susceptible to PD-L1 inhibitors as variants in the DNA sequences lead to the display of abnormal proteins on the tumor cell surface, allowing the immune system to attack the tumor in the absence of the PD-1/PD-L1 “off switch” [3]. The gene discussed is CD274; the disease is neoplasm.